阳 谭

阳谭 began their career in 2015 as a Platform Development Specialist at Sartorius Stedim Biotech. In 2018, they moved to Merck Chemical Technology (Shanghai) Co., Ltd. as a Global Proposal & Integrated Solutions Consultant. In 2021, they took on two roles, Director of MSAT at RVAC Medicines and Process Technology Consultant-Viral Based Thera at Sartorius. As Director of MSAT, they were responsible for technical transfer among R&D department, manufacture sites in China and other facilities within RVAC organization, as well as to & from CDMOs of RVAC’s choice and and provide technical guidance to reports and cross functional asset teams in areas of process tech transfer, process design and scale-up, facility fit, gap analysis, FMEA risk assessment, trouble shooting and investigation. As Process Technology Consultant-Viral Based Thera, they were responsible for providing technical guidance and support to customers.

阳谭 obtained a Master's degree in Biotechnology from Anhui University between 2000 and 2007.